Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. The company's lead product candidate, Rhopressa, is a once-daily eye drop that reduces intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Aerie's second product candidate, Roclatan, is a once-daily eye drop that combines Rhopressa with latanoprost, a widely prescribed PGA. Aerie is also focused on developing additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration (AMD) and diabetic macular edema (DME).